New Biomarker Assay Detects Neuroblastoma With Greater Sensitivity
Improved disease assessment aids in prediction of relapse in children
Investigators at The Saban Research Institute of Children’s Hospital Los Angeles have developed and tested a new biomarker assay for quantifying disease and detecting the presence of neuroblastoma even when standard evaluations yield negative results for the disease. In a study, led by Araz Marachelian, MD, of the Children’s Center for Cancer and Blood Diseases, researchers provide the first systematic comparison of standard imaging evaluations versus the new assay that screens for five different neuroblastoma-associated genes and determine that the new assay improves disease assessment and provides prediction of disease progression. Neuroblastoma is a cancer of the nervous system that exists outside the brain and typically is diagnosed in children five years or age or younger. Forty-five percent of patients have high-risk, metastatic tumors (stage 4) when diagnosed.
Click here to read more.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
2017 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 30-Sept. 2, 2017; Chicago
Mayo Clinic Neuroscience and Oncology Innovation Summit 2017
Sept. 7-9, 2017; Orlando, Fla.
63rd Annual Meeting of the Western Neurological Society
Sept. 8-11, 2017; Banff, Alberta, Canada
6th Homburger Neuroendoscopy Week
Sept. 11-15, 2017; Germany
Be the first to reply using the above form.